Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bs 100 141
2. Bs-100-141
3. Bs100141
4. Estulic
5. Guanfacine
6. Guanfacine Monohydrochloride
7. Hydrochloride, Guanfacine
8. Lon798
9. Monohydrochloride, Guanfacine
10. Tenex
1. 29110-48-3
2. Guanfacine Hcl
3. Tenex
4. Intuniv
5. Guanfacine (hydrochloride)
6. N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide Hydrochloride
7. Estulic
8. Bs 100-141
9. 29520-14-7
10. N-(aminoiminomethyl)-2,6-dichlorobenzeneacetamide Hydrochloride
11. Spd503
12. N-amidino-2-(2,6-dichlorophenyl)acetamide Hydrochloride
13. N-amidino-2-(2,6-dichlorophenyl)acetamide Monohydrochloride
14. Guafacine Hydrochloride
15. Bs-100-141
16. Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, Monohydrochloride
17. Spd 503
18. Mls000069745
19. Pml56a160o
20. Smr000058453
21. 29110-48-3 (hcl)
22. Dsstox_cid_25157
23. Dsstox_rid_80708
24. Dsstox_gsid_45157
25. Connexyn
26. Lon 798
27. N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide;hydrochloride
28. Cas-29520-14-7
29. Guanfacinehcl
30. Tenex (tn)
31. Guanfacinehydrochloride
32. Sr-01000075893
33. Ncgc00015469-05
34. Einecs 249-443-3
35. N-(aminoiminomethyl)-2,6-dichlorophenylacetamide Monohydrochloride
36. Unii-pml56a160o
37. Spd-503
38. Prestwick_740
39. Guanfacine Hydrochloride (jan/usp)
40. Intuniv (tn)
41. Mfcd00798230
42. Guanfacine Hydrochloride [usan:usp:jan]
43. Opera_id_1928
44. N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide Hydrochloride
45. Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, Hydrochloride (1:1)
46. G 1043
47. Schembl41681
48. Mls001077329
49. Mls002222252
50. [(2,6-dichlorophenyl)acetyl]guanidine Hydrochloride
51. Chebi:5559
52. Chembl1200494
53. Dtxsid2045157
54. Schembl15603414
55. Hms1569c19
56. Hms3747e15
57. Pharmakon1600-01505435
58. Bcp21710
59. N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide Hydrochloride
60. Tox21_110159
61. Tox21_500519
62. Guanfacine Hydrochloride [mi]
63. Nsc759121
64. S4693
65. Guanfacine Hydrochloride [jan]
66. Akos015966858
67. Akos030242245
68. Tox21_110159_1
69. Ccg-213439
70. Ccg-220339
71. Cs-1254
72. Guanfacine Hydrochloride [usan]
73. Lp00519
74. Guanfacine Hydrochloride [mart.]
75. Guanfacine Hydrochloride [vandf]
76. Guanfacine Hydrochloride [usp-rs]
77. Guanfacine Hydrochloride [who-dd]
78. Ncgc00015469-09
79. Ncgc00093914-01
80. Ncgc00093914-02
81. Ncgc00180965-01
82. Ncgc00261204-01
83. As-12253
84. Hy-17416
85. Guanfacine Hydrochloride, >=98% (hplc)
86. Bs100-141
87. Db-047525
88. Eu-0100519
89. Ft-0630546
90. Ft-0698181
91. G0414
92. Guanfacine Hydrochloride [orange Book]
93. D00606
94. Guanfacine Hydrochloride [usp Monograph]
95. T72238
96. A826918
97. J-017395
98. S-877503
99. Sr-01000075893-1
100. Sr-01000075893-3
101. Sr-01000075893-6
102. Q27286641
103. N-carbamimidoyl-2-(2,6-dichlorophenyl)-acetamide Hydrochloride
104. Guanfacine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
105. Guanfacine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
106. N-[bis(azanyl)methylidene]-2-[2,6-bis(chloranyl)phenyl]ethanamide Hydrochloride
Molecular Weight | 282.5 g/mol |
---|---|
Molecular Formula | C9H10Cl3N3O |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 2 |
Exact Mass | 280.988945 g/mol |
Monoisotopic Mass | 280.988945 g/mol |
Topological Polar Surface Area | 81.5 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 256 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Guanfacine hydrochloride |
Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
Active Ingredient | Guanfacine hydrochloride |
Dosage Form | Tablet, extended release; Tablet |
Route | oral; Oral |
Strength | eq 4mg base; eq 2mg base; 1mg; eq 1mg base; eq 3mg base; 4mg; 2mg; 3mg |
Market Status | Tentative Approval; Prescription |
Company | Twi Pharms; Epic Pharma; Teva Pharms Usa; Sandoz; Watson Labs; Actavis Elizabeth; Amneal Pharm; Mylan |
2 of 4 | |
---|---|
Drug Name | Tenex |
PubMed Health | Guanfacine (By mouth) |
Drug Classes | Antihypertensive, Cardiovascular Agent, Central Nervous System Agent |
Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
Active Ingredient | Guanfacine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 2mg base; eq 1mg base |
Market Status | Prescription |
Company | Promius Pharma |
3 of 4 | |
---|---|
Drug Name | Guanfacine hydrochloride |
Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
Active Ingredient | Guanfacine hydrochloride |
Dosage Form | Tablet, extended release; Tablet |
Route | oral; Oral |
Strength | eq 4mg base; eq 2mg base; 1mg; eq 1mg base; eq 3mg base; 4mg; 2mg; 3mg |
Market Status | Tentative Approval; Prescription |
Company | Twi Pharms; Epic Pharma; Teva Pharms Usa; Sandoz; Watson Labs; Actavis Elizabeth; Amneal Pharm; Mylan |
4 of 4 | |
---|---|
Drug Name | Tenex |
PubMed Health | Guanfacine (By mouth) |
Drug Classes | Antihypertensive, Cardiovascular Agent, Central Nervous System Agent |
Drug Label | Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with 2-adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetam... |
Active Ingredient | Guanfacine hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 2mg base; eq 1mg base |
Market Status | Prescription |
Company | Promius Pharma |
Intuniv is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.
Intuniv must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
C02AC02
Date of Issue : 2022-03-18
Valid Till : 2025-05-28
Written Confirmation Number : WC-0019
Address of the Firm :
NDC Package Code : 12598-9508
Start Marketing Date : 2014-03-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-02-26
Pay. Date : 2013-02-05
DMF Number : 8590
Submission : 1990-06-12
Status : Active
Type : II
NDC Package Code : 53296-0024
Start Marketing Date : 2010-03-17
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (75kg/75kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-02-24
Pay. Date : 2014-06-19
DMF Number : 28312
Submission : 2014-05-19
Status : Active
Type : II
NDC Package Code : 46016-2911
Start Marketing Date : 2022-03-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39404
Submission : 2024-01-11
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-08-01
Pay. Date : 2014-07-29
DMF Number : 8661
Submission : 1990-07-12
Status : Active
Type : II
Registration Number : 227MF10293
Registrant's Address : Calle Dulcinea, s/n 28805 Alcala De Henares Madrid Spain
Initial Date of Registration : 2015-12-24
Latest Date of Registration : --
NDC Package Code : 53069-0080
Start Marketing Date : 1995-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-10-14
Pay. Date : 2020-09-08
DMF Number : 34653
Submission : 2020-03-26
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-07-21
Written Confirmation Number : WC-0062
Address of the Firm :
NDC Package Code : 53747-096
Start Marketing Date : 2020-03-26
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-11-18
Pay. Date : 2016-08-23
DMF Number : 28049
Submission : 2014-03-07
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-10-27
Pay. Date : 2014-07-15
DMF Number : 28443
Submission : 2014-08-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36431
Submission : 2021-12-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4784
Submission : 1982-12-06
Status : Inactive
Type : II
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : Complete
Rev. Date : 2013-02-26
Pay. Date : 2013-02-05
DMF Number : 8590
Submission : 1990-06-12
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-11-18
Pay. Date : 2016-08-23
DMF Number : 28049
Submission : 2014-03-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36431
Submission : 2021-12-23
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-02-24
Pay. Date : 2014-06-19
DMF Number : 28312
Submission : 2014-05-19
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-08-01
Pay. Date : 2014-07-29
DMF Number : 8661
Submission : 1990-07-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4784
Submission : 1982-12-06
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4985
Submission : 1983-04-22
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-10-27
Pay. Date : 2014-07-15
DMF Number : 28443
Submission : 2014-08-04
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-10-14
Pay. Date : 2020-09-08
DMF Number : 34653
Submission : 2020-03-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39404
Submission : 2024-01-11
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2021-12-20
Date Granted : 2010-04-20
Brand Name : INTUNIV XR
Patent Number : 2432178
Filing Date : 2001-12-20
Strength per Unit : 1 mg
Dosage Form : Extended Release Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2021-12-20
Date Granted : 2010-04-20
Patent Expiration Date : 2021-12-20
Date Granted : 2010-04-20
Brand Name : INTUNIV XR
Patent Number : 2432178
Filing Date : 2001-12-20
Strength per Unit : 2 mg
Dosage Form : Extended Release Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2021-12-20
Date Granted : 2010-04-20
Patent Expiration Date : 2021-12-20
Date Granted : 2010-04-02
Brand Name : INTUNIV XR
Patent Number : 2432178
Filing Date : 2001-12-20
Strength per Unit : 3 mg
Dosage Form : Extended Release Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2021-12-20
Date Granted : 2010-04-02
Patent Expiration Date : 2021-12-20
Date Granted : 2010-04-20
Brand Name : INTUNIV XR
Patent Number : 2432178
Filing Date : 2001-12-20
Strength per Unit : 4 mg
Dosage Form : Extended Release Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2021-12-20
Date Granted : 2010-04-20
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?